Loading…
Q/c Technologies Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in QCLS.
▼ -100.0% over 5Y.
today you would have $0.04▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.99 | $115.00 | $777.00 | $3,450.00 | $18,180.00 | $11,940.00 | $19,200.00 | $162,720.00 | $154,368.00 | $2,188,800.00 | $1,393,920.00 | $4,596,480.00 | |
| P/S | 4.8x | — | — | — | — | — | — | 5.5x |
Companies of similar size in Technology, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BMRBeamr Imaging Ltd. | $1.24 | — | 1.6x | — | -48.40% | $19.26M |
| INTZIntrusion Inc | $0.79 | — | 6.5x | — | -140.96% | $19.47M |
| FOXXFoxx Development Holdings Inc. | $2.70 | — | — | — | — | $19.01M |
| ILLRTriller Group Inc. | $0.96 |
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Company description provided by Yahoo Finance.
| 8.5x |
| 3.3x |
| 5.9x |
| 3.3x |
| 4.2x |
| P/B | 1.4x | 1.4x | 1.2x | 1.4x | 3.1x | 9.8x | — | — | 2.4x | 1.5x | 5.2x | 1.1x | 1.2x |
| EPS | -$8.66 | -$1,080.87 | -$533.00 | -$1,174.00 | -$2,550.00 | -$14,940.00 | -$38,100.00 | -$133,680.00 | -$905,760.00 | -$702,720.00 | -$2,085,120.00 | -$760,320.00 |
| Profit margin | -233.07% | — | — | — | — | — | — | -246.55% | -651.37% | -219.58% | -111.57% | -440.27% | -70.99% |
| ROE | -100.47% | -53.45% | -238.61% | -32.34% | -103.42% | -126.40% | — | — | -185.97% | -97.53% | -97.52% | -141.02% | -21.23% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $19.57M |
| TGHLGrowHub Ltd | $0.75 | — | — | — | — | $18.89M |
| MOBXMobix Labs Inc | $1.11 | — | 3.0x | — | -1121.69% | $18.84M |